文献速递垂体与肾上腺疾病

组蛋白去乙酰化酶抑制剂SAHA是库欣病的有前景治疗方法

Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

研究在AtT-20细胞、异种移植裸鼠模型及8例人源性促肾上腺皮质激素肿瘤中测试SAHA疗效。SAHA降低细胞存活与ACTH分泌,缩小肿瘤并逆转ACTH升高,提示其可能用于复发/未缓解库欣病。

要点

  • SAHA(1 µM)使AtT-20细胞存活率24小时降至75%、48小时降至43%(方差分析 P=0.002)。
  • SAHA(1 µM)3小时使分泌ACTH显著下降70%(P<0.0001),并降低POMC转录。
  • 裸鼠异种移植中腹腔注射SAHA 5天使肿瘤缩小并逆转ACTH升高(P<0.0001)。

核心结论

  • SAHA可降低AtT-20及人源性促肾上腺皮质激素肿瘤细胞的存活与ACTH分泌,为复发/未缓解库欣病提供潜在干预手段。

研究设计与样本

  • 在AtT-20细胞中检测细胞活力、ACTH分泌(酶联免疫吸附试验)、凋亡及基因表达谱。
  • 在无胸腺裸鼠AtT-20异种移植模型中检测体内疗效。
  • 在体外检测SAHA对人源性促肾上腺皮质激素肿瘤(hCtT,n=8)的疗效。
  • 研究地点为国家卫生研究院(National Institutes of Health)。
  • 干预为SAHA(0.5至8 µM)。

主要发现

  • SAHA(1 µM)使AtT-20细胞存活率24小时降至75%、48小时降至43%(方差分析 P=0.002)。
  • SAHA(1 µM)3小时使分泌ACTH显著下降70%(P<0.0001),并降低POMC转录。
  • SAHA(1 µM)降低AtT-20细胞中LXRα,但不降低正常小鼠促肾上腺皮质激素细胞中的LXRα。
  • 裸鼠异种移植中腹腔注射SAHA 5天观察到肿瘤缩小(126 ± 33/160 ± 35 vs 337 ± 49 mm3;P=0.0005),并逆转ACTH升高(P<0.0001)。
  • SAHA(1 µM/24 h)降低hCtT存活率(78.92%;P=0.0007)和ACTH分泌(83.64%;P=0.03)。

关键数值与推荐

  • SAHA(1 µM)使AtT-20细胞存活率24小时为75%、48小时为43%(方差分析 P=0.002)。
  • SAHA(1 µM)3小时使分泌ACTH下降70%(P<0.0001)。
  • 裸鼠异种移植肿瘤体积:126 ± 33/160 ± 35 vs 337 ± 49 mm3(P=0.0005)。
  • SAHA(1 µM/24 h)使hCtT存活率为78.92%(P=0.0007),ACTH分泌为83.64%(P=0.03)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Remission failure following transsphenoidal surgery in Cushing disease (CD) from pituitary corticotroph tumors (CtTs) remains clinically challenging. Histone deacetylase inhibitors (HDACis) are antitumor drugs approved for clinical use, with the potential to affect adrenocorticotropin hormone (ACTH) hypersecretion by inhibiting pro-opiomelanocortin (POMC) transcription. OBJECTIVE: Testing the efficacy of suberoylanilide hydroxamic acid (SAHA) on human and murine ACTH-secreting tumor (AtT-20) cells. DESIGN: Cell viability, ACTH secretion (enzyme-linked immunosorbent assay), apoptosis, and gene expression profile were investigated on AtT-20 cells. In vivo efficacy was examined in an athymic nude mouse AtT-20 xenograft model. SAHA efficacy against human-derived corticotroph tumor (hCtT) (n = 8) was tested in vitro. SETTING: National Institutes of Health. INTERVENTION: SAHA (0.5 to 8 µM). MAIN OUTCOME MEASURES: AtT-20 and hCtT cell survival, in vitro/invivo ACTH measurements. RESULTS: SAHA (1 µM) reduced AtT-20 viability to 75% at 24 hours, 43% at 48 hours (analysis of variance; P = 0.002). Apoptosis was confirmed with elevated BAX/Bcl2 ratio and FACS. Intriguingly, early (3-hour) significant decline (70%; P < 0.0001) of secreted ACTH and diminished POMC transcription was observed with SAHA (1 µM). Microarray analysis revealed a direct association between liver X receptor alpha (LXRα) and POMC expression. Accordingly, SAHA reduced LXRα in AtT-20 cells but not in normal murine corticotrophs. Xenografted nude-mice tumor involution (126 ± 33/160 ± 35 vs 337 ± 49 mm3; P = 0.0005) was observed with 5-day intraperitoneal SAHA, with reversal of elevated ACTH (P < 0.0001). SAHA did not affect serum ACTH in nontumor mice. Lastly, we confirmed that SAHA (1 µM/24 h) decreased hCtT survival (78.92%; P = 0.0007) and ACTH secretion (83.64%; P = 0.03). CONCLUSION: Our findings demonstrate SAHA's efficacy in reducing survival and ACTH secretion in AtT-20 and hCtT cells, providing a potential intervention for recurrent/unremitting CD.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lu J, Chatain GP, Bugarini A, et al. Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease. J Clin Endocrinol Metab. 2017. PMID: 28505327. doi:10.1210/jc.2017-00464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。